- Home
- NCMI vs KZR Comparison
NCMI vs KZR Comparison
Compare NCMI & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCMI
- KZR
- Stock Information
- Founded
- NCMI 2005
- KZR 2015
- Country
- NCMI United States
- KZR United States
- Employees
- NCMI N/A
- KZR N/A
- Industry
- NCMI Advertising
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- NCMI Consumer Discretionary
- KZR Health Care
- Exchange
- NCMI Nasdaq
- KZR Nasdaq
- Market Cap
- NCMI 434.8M
- KZR 29.7M
- IPO Year
- NCMI 2007
- KZR 2018
- Fundamental
- Price
- NCMI $4.89
- KZR $3.75
- Analyst Decision
- NCMI Strong Buy
- KZR Hold
- Analyst Count
- NCMI 4
- KZR 2
- Target Price
- NCMI $7.00
- KZR $9.00
- AVG Volume (30 Days)
- NCMI 430.1K
- KZR 30.2K
- Earning Date
- NCMI 11-04-2025
- KZR 11-11-2025
- Dividend Yield
- NCMI 2.46%
- KZR N/A
- EPS Growth
- NCMI N/A
- KZR N/A
- EPS
- NCMI N/A
- KZR N/A
- Revenue
- NCMI $235,300,000.00
- KZR N/A
- Revenue This Year
- NCMI $5.40
- KZR N/A
- Revenue Next Year
- NCMI $14.48
- KZR N/A
- P/E Ratio
- NCMI N/A
- KZR N/A
- Revenue Growth
- NCMI 13.34
- KZR N/A
- 52 Week Low
- NCMI $4.12
- KZR $3.62
- 52 Week High
- NCMI $7.60
- KZR $9.18
- Technical
- Relative Strength Index (RSI)
- NCMI 60.91
- KZR 36.39
- Support Level
- NCMI $4.28
- KZR $3.76
- Resistance Level
- NCMI $4.57
- KZR $4.05
- Average True Range (ATR)
- NCMI 0.17
- KZR 0.13
- MACD
- NCMI 0.07
- KZR 0.00
- Stochastic Oscillator
- NCMI 91.89
- KZR 0.00
About NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.